Abstract
Enhanced cardiac generation of peroxynitrite contributes to septic cardiomyopathy. Since matrix metalloproteinases (MMPs) are activated in vitro by peroxynitrite, we hypothezised that MMPs may contribute to cardiac mechanical dysfunction in sepsis. Rats were injected (i.p.) with either lipopolysaccharide (LPS, 4 mg/kg) or vehicle. MMP inhibitors, either Ro 31-9790 (20 mg/kg), doxycycline (4 mg/kg), or vehicle were administered i.p. 30 min after LPS. At 6 h, when the symptoms of endotoxemia peak, hearts were excised and perfused as working hearts with Krebs-Henseleit buffer at 37°C. Cardiac work (cardiac output x peak systolic pressure product) was measured. Perfusate and ventricle samples were analyzed by gelatin zymography to quantify MMP activity.
Cardiac function was significantly depressed in LPS-treated rats compared to control rats (control: 55 ± 4, LPS: 26 #x00B1; 6 mmHg*mL*min−1). LPS also caused a loss of 72 kDa MMP-2 activity in the ventricles and the perfusate. Although MMP-9 activity was not detected in the ventricles, LPS resulted in an increase in perfusate 92 kDa MMP-9 activity. The MMP inhibitors significantly improved cardiac function of LPS-treated rats (Ro 31−9790: 38 ± 3, doxycycline: 51 ± 3 mmHg*mL*min−1), had no effect on the loss of MMP-2 activity, and significantly reduced the MMP-9 activity in the perfusate. These results demonstrate, for the first time, that LPS induced cardiac dysfunction is associated with a loss in ventricular MMP-2 activity and the release of MMP-9 from the heart. MMP inhibitors can significantly preserve cardiac mechanical function during septic shock.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874, 1992
Grocott-Mason RM, Shah AM: Cardiac dysfunction in sepsis: New theories and clinical implications. Intensive Care Med 24: 286–295, 1998
Titheradge MA: Nitric oxide in septic shock. Biochim Biophys Acta 1411:437–455, 1999
Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good the bad, and the ugly. Am J Physiol 271: CI424– C1437, 1996
Kooy NW, Lewis SJ, Royall J A, Ye YZ, Kelly DR, Beckman JS: Extensive tyrosine nitration in human myocardial inflammation: Evidence for the presence of peroxynitrite. Crit Care Med 25: 812–819, 1997
Kooy NW, Royall J A, Ye YZ, Kelly DR, Beckman JS: Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med 151: 1250–1254, 1995
Khadour FH, Panas DL, Ferdinandy P, Schulze CJ, Csont T, Lalu MM, Wildhirt SM, Schulz R: Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol 283: H1108– Hl115, 2002
Kamisaki Y, Wada K, Ataka M, Yamada Y, Nakamoto K, Ashida K, Kishimoto Y: Lipopolysaccharide-induced increase in plasma nitrotyrosine concentrations in rats. Biochim Biophys Acta 1362:24–28,1997
Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90: 251–262, 2002
Creemers EE, Cleutjens JP, Smits JF, Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 89: 201–210, 2001
Cheung P-Y, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833–1839, 2000
Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543–1549, 2002
Fernandez-Patron C, Radomski MW, Davidge SM: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906–911, 1999
Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87: 670–676, 2000
Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW: Release of gelatinase A during platelet activation mediates aggregation. Nature 386:616–619, 1997
Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H: Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276: 29596–29602, 2001
Schulz R, Nava E, Moncada S: Induction and potential biological relevance of Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105: 575–580, 1992
Ferdinandy P, Panas D, Schulz R: Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol 276: H1861–H1867, 1999
Ferdinandy P, Daniel H, Ambrus I, Rothery R, Schulz R: Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87: 241–247, 2000
Keliner DE, Stetler-Stevenson WG: Quantitative zymography: Detection of picogram quantities of gelatinases. Anal Biochem 218: 325–329,1994
Yu AE, Murphy AN, Stetler-Stevenson WG: 72-kDa gelatinase (gelatinase A): Structure, activation, regulation, and substrate specificity. In: W. Parks, R. Mecham (eds). Matrix Metalloproteinases. Academic Press, San Diego, 1998, pp 85–114
Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, Feldman LJ: Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-l secretion. Cardiovasc Res 49: 882–890, 2001
Peterson JT, Hallak H, Johnson L, Li H, O’Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303–2309, 2001
Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944–1949, 2000
Li YY, Feldman AM, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728–1734, 1998
Yasmin W, Strynadka KD, Schulz R: Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33: 422–432, 1997
Qun Gao C, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R: Matrix metalloproteinase-2 mediates cytokineinduced myocardial contractile dysfunction. Cardiovasc Res 57: 426– 433, 2002
Huhtala P, Chow LT, Tryggvason K: Structure of the human type IV collagenase gene. J Biol Chem 265: 11077–11082, 1990
Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425–10432, 1993
Wang W, Sawicki G, Schulz R: Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 53: 165–174,2002
Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H: Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 316: 355–360, 1998
Balduyck M, Albani D, Jourdain M, Mizon C, Tournoys A, Drobecq H, Fourrier F, Mizon J: Inflammation-induced systemic proteolysis of inter-alpha-inhibitor in plasma from patients with sepsis. J Lab Clin Med 135: 188–198,2000
Smith GN Jr, Mickler EA, Hasty KA, Brandt KD: Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme. Arthritis Rheum 42: 1140–1146,1999
Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y: Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket. J Med Chem 41: 1209–1217, 1998
Vieillard-Baron A, Frisdal E, Eddahibi S, D eprez I, Baker AH, Newby AC, Berger P, Levame M, Raffestin B, Adnot S, d'Ortho MP: Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 87: 418–425,2000
Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A: Role of matrix metalloproteinases in blood flow-induced arterial enlargement: Interaction with NO. Arterioscler Thromb Vase Biol 20: El20–E126,2000
Hewson AK, Smith T, Leonard JP, Cuzner ML: Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31–9790. Inflamm Res 44: 345–349,1995
Siebert H, Dippel N, Mader M, Weber F, Bruck W: Matrix metalloproteinase expression and inhibition after sciatic nerve axotomy. J Neuropathol Exp Neurol 60: 85–93, 2001
Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063–3070, 1999
Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT: Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105: 753–758, 2002
Weber KT, Sun Y, Tyagi SC, Cleutjens JP: Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26: 279–292, 1994
Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C: Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: Potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1: 337–352, 1999
Ammann P, Fehr T, Minder EI, Gunter C, Bertel O: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 27: 965–969, 2001
Turner A, Tsamitros M, Bellomo R: Myocardial cell injury in septic shock. Crit Care Med 27: 1775–1780, 1999
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lalu, M.M., Gao, C.Q., Schulz, R. (2003). Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. In: Kirshenbaum, L.A., Dixon, I.M.C., Singal, P.K. (eds) Biochemistry of Hypertrophy and Heart Failure. Developments in Molecular and Cellular Biochemistry, vol 43. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9238-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9238-3_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4853-5
Online ISBN: 978-1-4419-9238-3
eBook Packages: Springer Book Archive